INT21840

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1990
Last Reported 2007
Negated 0
Speculated 1
Reported most in Abstract
Documents 20
Total Number 21
Disease Relevance 14.44
Pain Relevance 2.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL3) extracellular region (IL3) cell-cell signaling (IL3)
Anatomy Link Frequency
leucocytes 3
platelets 3
eosinophils 3
reticulocytes 3
macrophage 1
IL3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 35 99.70 Very High Very High Very High
dexamethasone 3 96.84 Very High Very High Very High
lidocaine 4 95.68 Very High Very High Very High
Inflammation 11 95.36 Very High Very High Very High
Inflammatory marker 2 94.80 High High
headache 14 94.36 High High
Chronic pancreatitis 2 92.76 High High
vincristine 3 73.96 Quite High
Angina 3 71.88 Quite High
Pain 2 59.80 Quite High
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 6 99.98 Very High Very High Very High
Myocardial Infarction 9 99.28 Very High Very High Very High
Disease 18 98.98 Very High Very High Very High
Pancreatic Cancer 7 98.40 Very High Very High Very High
Sickle Cell Anemia 6 97.20 Very High Very High Very High
Asthma 75 97.00 Very High Very High Very High
Increased Venous Pressure Under Development 4 96.44 Very High Very High Very High
Lung Cancer 10 96.40 Very High Very High Very High
Adhesions 8 96.00 Very High Very High Very High
Chills 3 95.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This observation may increase the application of rhIL-3, for instance in combination with other hematopoietic growth factors.
Spec (may) Positive_regulation (increase) of rhIL-3
1) Confidence 0.70 Published 2002 Journal J. Exp. Ther. Oncol. Section Abstract Doc Link 12415620 Disease Relevance 0.32 Pain Relevance 0.12
Both leukocyte and platelet recovery were significantly enhanced in the rhIL-3 cycle.
Positive_regulation (enhanced) of rhIL-3 in platelet
2) Confidence 0.50 Published 2002 Journal J. Exp. Ther. Oncol. Section Abstract Doc Link 12415620 Disease Relevance 0.43 Pain Relevance 0.13
We performed an open labelled, phase I/II study in which patients received IL-3 by continuous infusion from 24 h before the beginning of chemotherapy until day 28.
Positive_regulation (received) of IL-3
3) Confidence 0.50 Published 1996 Journal Leukemia Section Abstract Doc Link 8558936 Disease Relevance 0.31 Pain Relevance 0
An increase in platelet counts from 1,000/microL to 31,000/microL was induced by rhIL-3 in one patient, and an increase in reticulocyte counts by more than 10,000/microL in four patients.
Positive_regulation (increase) of rhIL-3 in reticulocyte
4) Confidence 0.50 Published 1990 Journal Blood Section Abstract Doc Link 2207306 Disease Relevance 0.48 Pain Relevance 0.06
Pharmacokinetic studies were performed in 13 patients, and area under the curve and maximal concentration values increased with increasing rhIL-3 dose levels (P < 0.001) and correlated with maximal changes from baseline in WBC, neutrophils, and eosinophils. rhIL-3 antibodies were detected in 8% of patients by day 29 of cycle 1 but were not neutralizing. rhIL-3 is well tolerated when administered s.c. and has reproducible hematological and immunological effects.
Positive_regulation (increasing) of rhIL-3 in neutrophils
5) Confidence 0.50 Published 1996 Journal Clin. Cancer Res. Section Abstract Doc Link 9816178 Disease Relevance 0.62 Pain Relevance 0.11
Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor, which exhibits stimulatory effects on leucocytes, reticulocytes and platelets.
Positive_regulation (multipotent) of Interleukin-3 in platelets
6) Confidence 0.49 Published 1997 Journal Anticancer Drugs Section Abstract Doc Link 9095335 Disease Relevance 0.44 Pain Relevance 0.04
Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor, which exhibits stimulatory effects on leucocytes, reticulocytes and platelets.
Positive_regulation (multipotent) of IL-3 in platelets
7) Confidence 0.49 Published 1997 Journal Anticancer Drugs Section Abstract Doc Link 9095335 Disease Relevance 0.44 Pain Relevance 0.04
There was a significant increase in eosinophil count during rhIL-3 (p = 0.03 cycle 2 vs cycle 1 and p = 0.002 cycle 2 vs cycle 3) without accompanying clinical signs of symptoms.
Positive_regulation (increase) of rhIL-3 in eosinophil
8) Confidence 0.47 Published 1993 Journal Ann. Hematol. Section Abstract Doc Link 8218538 Disease Relevance 0.80 Pain Relevance 0.28
Subsequently, nine patients were added to the group receiving 10 micrograms/kg/d. 27 patients received IL-3 after their second course of ICE.
Positive_regulation (received) of IL-3
9) Confidence 0.44 Published 1994 Journal Br. J. Haematol. Section Abstract Doc Link 7986706 Disease Relevance 1.15 Pain Relevance 0.12
Twenty-one patients with relapsed Hodgkin's disease or intermediate/high-grade non-Hodgkin's lymphoma received rhIL-3 after the second cycle of DHAP chemotherapy (cisplatin, cytosine-arabinoside, dexamethasone).
Positive_regulation (received) of rhIL-3 associated with lymphatic system cancer, disease and dexamethasone
10) Confidence 0.44 Published 1993 Journal Ann. Hematol. Section Abstract Doc Link 8218538 Disease Relevance 0.59 Pain Relevance 0.10
In contrast, increasing concentrations of IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition.
Positive_regulation (increasing) of IL-3 in macrophage
11) Confidence 0.25 Published 1998 Journal J. Immunol. Section Abstract Doc Link 9605159 Disease Relevance 0.32 Pain Relevance 0.39
Both leukocyte and platelet recovery were significantly enhanced in the rhIL-3 cycle.
Positive_regulation (enhanced) of rhIL-3 in leukocyte
12) Confidence 0.17 Published 2002 Journal J. Exp. Ther. Oncol. Section Abstract Doc Link 12415620 Disease Relevance 0.43 Pain Relevance 0.13
Pharmacokinetic studies were performed in 13 patients, and area under the curve and maximal concentration values increased with increasing rhIL-3 dose levels (P < 0.001) and correlated with maximal changes from baseline in WBC, neutrophils, and eosinophils. rhIL-3 antibodies were detected in 8% of patients by day 29 of cycle 1 but were not neutralizing. rhIL-3 is well tolerated when administered s.c. and has reproducible hematological and immunological effects.
Positive_regulation (increasing) of rhIL-3 in eosinophils
13) Confidence 0.17 Published 1996 Journal Clin. Cancer Res. Section Abstract Doc Link 9816178 Disease Relevance 0.62 Pain Relevance 0.11
Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor, which exhibits stimulatory effects on leucocytes, reticulocytes and platelets.
Positive_regulation (multipotent) of Interleukin-3 in reticulocytes
14) Confidence 0.17 Published 1997 Journal Anticancer Drugs Section Abstract Doc Link 9095335 Disease Relevance 0.44 Pain Relevance 0.04
Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor, which exhibits stimulatory effects on leucocytes, reticulocytes and platelets.
Positive_regulation (multipotent) of IL-3 in reticulocytes
15) Confidence 0.17 Published 1997 Journal Anticancer Drugs Section Abstract Doc Link 9095335 Disease Relevance 0.44 Pain Relevance 0.04
Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor, which exhibits stimulatory effects on leucocytes, reticulocytes and platelets.
Positive_regulation (multipotent) of IL-3 in leucocytes
16) Confidence 0.17 Published 1997 Journal Anticancer Drugs Section Abstract Doc Link 9095335 Disease Relevance 0.44 Pain Relevance 0.04
Interleukin-3 (IL-3) is a multipotent hematopoietic growth factor, which exhibits stimulatory effects on leucocytes, reticulocytes and platelets.
Positive_regulation (multipotent) of Interleukin-3 in leucocytes
17) Confidence 0.17 Published 1997 Journal Anticancer Drugs Section Abstract Doc Link 9095335 Disease Relevance 0.44 Pain Relevance 0.04
CRP, M-CSF, and IL-3 were all increased in patients with AMI.
Positive_regulation (increased) of IL-3 associated with myocardial infarction
18) Confidence 0.09 Published 2007 Journal Angiology Section Abstract Doc Link 17351157 Disease Relevance 0.94 Pain Relevance 0.19
Of the cytokines studied, only IL-3 showed an increase during therapy, suggesting HU may induce early erythroid progenitors capable of producing HbF by a direct or indirect effect on IL-3 production.
Positive_regulation (increase) of IL-3 associated with cytokine
19) Confidence 0.04 Published 1998 Journal Acta Haematol. Section Abstract Doc Link 9691143 Disease Relevance 0.89 Pain Relevance 0.18
There were significant differences in the levels of circulating SCF, IL-3, GM-CSF, M-CSF, CEA and CA 19-9 in the pancreatic cancer patients compared to the control group.
Positive_regulation (circulating) of IL-3 associated with pancreatic cancer
20) Confidence 0.02 Published 2005 Journal Clin. Chem. Lab. Med. Section Abstract Doc Link 15843207 Disease Relevance 1.40 Pain Relevance 0.47

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox